Literature DB >> 31210943

Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites.

Benedikt Simbrunner1,2, Annika Röthenbacher1,2, Helmuth Haslacher3, David Bauer1,2, David Chromy1,2, Theresa Bucsics1,2, Philipp Schwabl1,2, Rafael Paternostro1,2, Bernhard Scheiner1,2, Michael Trauner1, Mattias Mandorfer1,2, Ilse Schwarzinger3, Thomas Reiberger1,2.   

Abstract

Background: Spontaneous bacterial peritonitis (SBP) is defined as an ascitic polymorphonuclear cell count (A-PMN) > 250 cells/µl. Objective: We aimed to investigate the prognostic value of ascitic fluid cell counts in patients without SBP. Patients and methods: A total of 178 patients were included and stratified by ascitic cell counts at index paracentesis: A-LEUK-low (<250/µl), A-LEUK-intermediate (250-500/µl) and A-LEUK-SBP (>500/µl) for leukocytes; A-PMN-low (<125/µl), A-PMN-intermediate (125-250/µl) and A-PMN-SBP (>250/µl) for PMN cells.
Results: One-year mortality was comparable between group A-LEUK-SBP (53.9%) and patients with subclinical cell counts (34.5% for A-LEUK-low, 43.5% for A-LEUK-intermediate, log-rank p = 0.547). However, we observed an increase in one-year mortality already in group A-PMN-intermediate with 75% and A-PMN-SBP with 80.9% (vs 40.5% for A-PMN-low, log-rank p = 0.016).Importantly, increases of A-PMN cell counts between two paracenteses were associated with increased mortality: per 100 cells/µl increase of absolute A-PMN cell count: hazard ratio (HR): 1.03 (95% confidence interval (CI): 1.01-1.06), p = 0.005; per 5% increase of relative PMN cell count: HR: 1.15 (95% CI: 1.06-1.26), p = 0.001.
Conclusion: Patients with PMN cell counts of 125-250/µl are at high risk for mortality, which was very similar to SBP patients with PMN cell counts >250/µl. This highlights the need for preventive strategies. The prognostic value of changes in relative ascitic PMN cell counts should be evaluated in future studies.

Entities:  

Keywords:  Ascites; cirrhosis; mortality; polymorphonuclear cells; spontaneous bacterial peritonitis

Year:  2019        PMID: 31210943      PMCID: PMC6545717          DOI: 10.1177/2050640619843000

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  36 in total

1.  Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis.

Authors:  Stefania Angeloni; Giorgia Nicolini; Manuela Merli; Francesca Nicolao; Giorgio Pinto; Teresa Aronne; Adolfo Francesco Attili; Oliviero Riggio
Journal:  Am J Gastroenterol       Date:  2003-08       Impact factor: 10.864

2.  Evaluation of the fully automated hematological analyzer Sysmex XE-5000 for flow cytometric analysis of peritoneal fluid.

Authors:  Giuseppe Lippi; Clarissa Cattabiani; Anna Benegiamo; Daniela Gennari; Fernanda Pavesi; Alberta Caleffi; Silvia Pipitone
Journal:  J Lab Autom       Date:  2013-01-23

3.  Diagnostic validity of flow cytometry vs manual counting of polymorphonuclear leukocytes in spontaneous bacterial peritonitis.

Authors:  Heba Ahmed Osman; Sanaa Shaker Aly; Eman M Salah-Eldin; Muhammad Abbas El-Masry; Mohammed H Hassan
Journal:  J Clin Lab Anal       Date:  2018-01-31       Impact factor: 2.352

4.  Relative Ascites Polymorphonuclear Cell Count Indicates Bacterascites and Risk of Spontaneous Bacterial Peritonitis.

Authors:  Philipp Lutz; Felix Goeser; Dominik J Kaczmarek; Stefan Schlabe; Hans Dieter Nischalke; Jacob Nattermann; Achim Hoerauf; Christian P Strassburg; Ulrich Spengler
Journal:  Dig Dis Sci       Date:  2017-06-09       Impact factor: 3.199

5.  Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.

Authors:  Vasiliki Arvaniti; Gennaro D'Amico; Giuseppe Fede; Pinelopi Manousou; Emmanuel Tsochatzis; Maria Pleguezuelo; Andrew Kenneth Burroughs
Journal:  Gastroenterology       Date:  2010-06-14       Impact factor: 22.682

6.  Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.

Authors:  Cristina Ripoll; Roberto Groszmann; Guadalupe Garcia-Tsao; Norman Grace; Andrew Burroughs; Ramon Planas; Angels Escorsell; Juan Carlos Garcia-Pagan; Robert Makuch; David Patch; Daniel S Matloff; Jaime Bosch
Journal:  Gastroenterology       Date:  2007-05-21       Impact factor: 22.682

7.  Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II).

Authors:  Markus Peck-Radosavljevic; Bernhard Angermayr; Christian Datz; Arnulf Ferlitsch; Monika Ferlitsch; Valentin Fuhrmann; Michael Häfner; Ludwig Kramer; Andreas Maieron; Berit Payer; Thomas Reiberger; Rudolf Stauber; Rudolf Steininger; Michael Trauner; Siegfried Thurnher; Gregor Ulbrich; Wolfgang Vogel; Heinz Zoller; Ivo Graziadei
Journal:  Wien Klin Wochenschr       Date:  2013-04-12       Impact factor: 1.704

8.  Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.

Authors:  M Assem; M Elsabaawy; M Abdelrashed; S Elemam; S Khodeer; W Hamed; A Abdelaziz; G El-Azab
Journal:  Hepatol Int       Date:  2015-12-10       Impact factor: 9.029

9.  MELD Score Is Not Related to Spontaneous Bacterial Peritonitis.

Authors:  Luciana Haddad; Tatiana Morgado Conte; Liliana Ducatti; Lucas Nacif; Luiz Augusto Carneiro D'Albuquerque; Wellington Andraus
Journal:  Gastroenterol Res Pract       Date:  2015-07-01       Impact factor: 2.260

10.  Bacterascites: A study of clinical features, microbiological findings, and clinical significance.

Authors:  Rosalie C Oey; Henk R van Buuren; David M de Jong; Nicole S Erler; Robert A de Man
Journal:  Liver Int       Date:  2018-08-10       Impact factor: 5.828

View more
  1 in total

Review 1.  Liver cirrhosis and immune dysfunction.

Authors:  Elda Hasa; Phillipp Hartmann; Bernd Schnabl
Journal:  Int Immunol       Date:  2022-09-06       Impact factor: 5.071

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.